Open Access

Effects of radioiodine administration on serum concentrations of matrix metalloproteinases, adiponectin and thrombospondin-1

  • Andrzej Lewinski1Email author,
  • Anna Brona2,
  • Krzysztof C Lewandowski1,
  • Diana Jedrzejuk2,
  • Anna Bohdanowicz-Pawlak2,
  • Elżbieta Skowronska-Jozwiak1,
  • Małgorzata Bienkiewicz3 and
  • Andrzej Milewicz2
Thyroid Research20136:9

DOI: 10.1186/1756-6614-6-9

Received: 17 July 2013

Accepted: 23 July 2013

Published: 6 August 2013

Abstract

Background

In order to assess safety of radioactive iodine administration in the treatment of thyrotoxicosis, we measured concentrations of matrix metalloproteinase-2 (MMP-2), its main inhibitor – TIMP-2 (tissue inhibitor of MMP-2), matrix metalloproteinase-9 (MMP-9), its main inhibitor – TIMP-1, adiponectin, as well as pro-inflammatory and procancerogenic thrombospondin-1 (TSP-1).

Design and patients

The study involved 23 patients treated with radioiodine for thyrotoxicosis. Serum concentrations of TSH, free T4, free T3, MMP-2, MMP-9, TIMP-1, TIMP-2, total adiponectin and TSP-1 were measured by immunoassays just before radioiodine administration (visit 1), and subsequently, after 7 days (visit 2), 3 months (visit 3), 6 to 8 months (visit 4) and 15–18 months after radioiodine administration (visit 5).

Results

There were no acute changes in serum concentrations of MMP-2, MMP-9, TIMP-1, TIMP-2, adiponectin and TSP-1 (visit 1 vs. 2). Subsequently, there was an increase in MMP-2 (from 393±106 ng/ml to 774±424 ng/ml), TIMP-1 (from 177±76 ng/ml to 296±118 ng/ml), and adiponectin (from 16442±9490 ng/ml to 23518±9840 ng/ml), visit 1 to 5, respectively (p < 0.01). Further analysis revealed no significant change in MMP-2/TIMP-2 ratio, but there was a significant decrease in MMP-9/TIMP-1 ratio (p < 0.05), suggestive of possible decrease in free MMP-9 concentrations.

Conclusions

Our data reveal a significant and sustained increase in serum adiponectin, as well as possible decrease of free MMP-9 concentration after radioiodine administration. In contrast, there was no significant change of TSP-1. This might indicate overall safety of radioiodine treatment of thyrotoxicosis in terms of the risks of subsequent cardiovascular and neoplastic disease.

Keywords

Metalloproteinases Adiponectin Thrombospondin Thyrotoxicosis Radioactive iodine

Background

The term matrix metalloproteinases (MMPs) refers to a group of enzymes that physiologically remodel extracellular matrix, but also contribute to development of various pathological states, such as neoplasms, inflammatory and cardiovascular diseases [1]. Furthermore, increased activity of MMPs in blood vessels has been implicated in formation of aneurysms [2], while formation of unstable atherosclerotic plaques, as a result of locally increased activity of MMPs, might in turn lead to an increased risk thrombotic and embolic events, including myocardial infarctions and strokes [35].

Adiponectin is a plasma protein secreted from adipocytes in relatively large amounts, where decreased adiponectin secretion has been directly linked with the development of type 2 diabetes mellitus and metabolic syndrome, known to be associated with an increased risk of cardiovascular disease. There is ample evidence demonstrating that adiponectin has anti-inflammatory, anti-atherosclerotic and vasoprotective actions, affects signaling in myocardial cells and exerts beneficial actions on the heart after pressure overload and ischemia-reperfusion injury [6, 7].

Thrombospondin-1 (TSP-1) is a member of a family of five (5) structurally related extracellular glycoproteins that plays a major role in cell-matrix and cell-cell interactions. TSP-1 is highly expressed in obese, insulin-resistant subjects. When released to the matrix, matricellular proteins associate with growth factors, cytokines, and other bioactive effectors and bind to cell surface receptors transducing signaling cascades. TSP-1 is highly correlated with adipose inflammation [8]; and is decreased by pioglitazone [9], though there is also evidence of possible protective properties in circumstances, such as cardiac remodeling after injury [10]. Thrombospondin has been also found to be secreted by thyrocytes in a pattern that is opposite to thyroglobulin [11], and subsequently TSP-1 has also been identified as a potential regulator of angiogenesis and tumour progression [12].

Recent studies [13, 14], demonstrated that even subclinical thyrotoxicosis may be independently associated, with an increased cardiovascular morbidity and mortality, though there are still several issues pertaining this subject [15]. Pharmacological treatment of thyrotoxicosis occasionally causes agranulocytosis, and this complication, unfortunately, cannot be prevented by routine full blood count monitoring of asymptomatic patients [16]. Pharmacological treatment of thyrotoxicosis has other drawbacks, as it generally does not lead to permanent cure in subjects with toxic multinodular goitre, while relapse in subjects with Graves’ disease may exceed 50 per cent. For these reasons radioactive iodine treatment (RIT) has been used to treat thyrotoxicosis since 1940's. In the USA, and less commonly in Europe, RIT is prescribed even for children with Graves’s disease [17]. There are, however, some recent data [18], suggestive of an increase in cardiovascular and cancer mortality after RIT, at least in some subjects, though a definite causality remains to be proven [19]. Given potential option of surgery, the safety of RIT is of paramount importance from the clinical view-point. For reasons outlined above, we have endeavoured to prospectively investigate whether serum concentrations of selected risk markers of cardiovascular and neoplastic diseases, such as matrix metalloproteinases (MMP-2, MMP-9), their inhibitors (TIMP-1, TIMP-2), adiponectin and TSP-1 might change following radioiodine treatment of thy-rotoxicosis.

Design and patients

The study involved 23 patients (three males) age 53±12 (mean±SD), BMI 26.5±4.6 kg/m2 years treated with radioiodine for thyrotoxicosis. Serum concentrations TSH, free T4, free T3, MMP-2, MMP-9, TIMP-1, TIMP-2, total adiponectin and TSP-1 were measured just before radioiodine administration (visit 1), and subsequently, after 7 days (visit 2), 3 months (visit 3), 6 to 8 months (visit 4) and 15–18 months after radioiodine administration (visit 5).

Radioactive iodine was administered according to the protocol that involved thyroid goitre or nodule volume and radioiodine uptake (T24) and radioiodine activity for 1.0 gram of thyroid tissue in thyroid with dose depending on the type of thyroid disease. In this method the formula applied for calculation of the dose of radioiodine was as follows [20]:
Dose of radioiodine mCi = Thyroid mass g × radioiodine activity for 1.0 g of thyroid tissue μCi / g T 24 % × 10

where:

-1.0 g of thyroid tissue mass means 1.0 ml of thyroid volume,
  • radioiodine activity to be administered in adults: in Graves’ disease 80–150 μCi/1.0 g of thyroid tissue, in toxic thyroid nodule 150 μCi/1.0 g of thyroid tissue, in toxic goitre 100-150 μCi/1.0 g of thyroid tissue [21],

  • T24 (%) - radioiodine uptake [20].

Measurements of MMP-2, MMP-9, TIMP-1, TIMP-2, adiponectin and TSP-1 were performed by R & D systems immunoassays (Human Quantikine ELISA kit, for MMPs and TIMPs, Human Total Adiponectin /Acrp30 Quantikine ELISA Kit, human TSP-1 Quantikine ELISA Kit - catalogue numbers: DMP2F0 for MMP-2, DMP900 for MMP-9, DTM100 for TIMP-1, DTM200 for TIMP-2, DRP300 for adiponectin and DTSP10 for TSP-1).

Statistical analysis

Given the dependent character of the data (repeated measurements in the same subjects), the data were analysed by means of simple descriptive statistics of location and dispersion as well as Friedman ANOVA for dependent samples. If the observed difference between all measurements was significant post hoc Tukey’s test was performed. Statistical significance was considered to be achieved for p ≤ 0.05. All the calculations were performed by means of Statistica v 9.0 computer software.

The study was approved by the Ethics Committee of the Medical University of Lodz, Poland.

Results

Results of the study are presented in Tables 1, 2 and 3 and Figures 1, 2, 3 and 4. Following radioiodine treatment there was a fall in free T4 between visit 2 and visit 3 (p < 0.01), however, as patients later developing hypothyroidism were treated with L-thyroxine, then the concentrations of free T4 remained stable at subsequent visits. Changes of TSH, free T4, free T3, glucose and lipids at the beginning and at the end of the study are presented in Table 1. Concentrations of other parameters, measured at subsequent visits (1–5) are presented in Table 2. There were no acute changes in serum concentrations of MMP-2, MMP-9, TIMP-1, TIMP-2, adiponectin and TSP-1 (visit 1 vs. visit 2). There was no significant change in serum concentrations of TSP-1 throughout the study (Table 2, Figure 1). In contrast to TSP-1, there was, however, an increase in serum adiponectin (already significant at visit 3, p < 0.05), that remained significant for further duration of the study and (16442±9490 ng/ml at visit 1 (before radioiodine administration) vs. to 23518±9840 ng/ml, at visit 5 (15–18 months after radioiodine administration), p < 0.01, Table 2, Figure 2.
Table 1

Concentrations of TSH, free T4, free T3, glucose and lipids at the beginning and at the end of the study (visit 1 vs. visit 5)

 

Before radioiodine (Visit 1)

15-18 months post radioiodine (Visit 5)

p- value

 

Mean

SD

Mean

SD

 

TSH* [μIU/ml]

0.10

0.20

3.74

3.15

0.0003

Free T4* [pmol/l]

26.8

15.6

14.42

2.23

0.0008

Free T3* [pmol/l]

10.1

5.3

4.87

1.01

0.0003

Glucose [mg/dl]

93

13

90

12

0.62

Total cholesterol [mg/dl]

197

37

237

56

0.012

LDL-cholesterol [mg/dl]

108

38

153

54

0.001

HDL-cholesterol [mg/dl]

61

17

61

14

0.16

Triglycerides [mg/dl]

121

118

116

58

0.21

*Reference ranges: free T4 11.5-22.7 pmol/l, free T3 2.76-6.45 pmol/l, TSH 0.4-4 μIU/ml 1 pmol/l x 0.0777= ng/dl.

Table 2

Descriptive statistics for serum concentrations of matrix metaloproteinases (MMP-2, MMP-9), tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2), adiponectin and thrombospondin-1 (TSP-1) at five (5) consecutive visits – before and after radioiodine therapy, presented with probability values (p-values) of Kruskal-Wallis’ ANOVA for repeated measures design

 

VISIT:

n

Mean ± SD

p-value

MMP-2 [ng/ml]

before radioiodine

23

393 ± 106

0.001

7 days post

23

373 ± 88

3 months post

23

423 ± 115

6 - 8 months post

23

452 ± 124

15-18 months post

17

774 ± 424

MMP-9 [ng/ml]

before radioiodine

23

631 ± 327

0.68

7 days post

23

594 ± 353

3 months post

23

704 ± 364

6 - 8 months post

23

714 ± 430

15-18 months post

17

470 ± 106

TIMP-1 [ng/ml]

before radioiodine

23

177 ± 76

0.00001

7 days post

23

186 ± 54

3 months post

23

215 ± 86

6 - 8 months post

23

263 ± 128

15-18 months post

17

296 ± 118

TIMP-2 [ng/ml]

before radioiodine

23

136 ± 44

0.36

7 days post

23

143 ± 36

3 months post

23

161 ± 39

6 -8 months post

23

153 ± 39

15-18 months post

17

168 ± 41

Adiponectin [ng/ml]

before radioiodine

23

16442 ±9490

0.001

7 days post

23

14430 ± 6216

3 months post

23

21300 ± 8908

6 - 8 months post

23

20005 ± 8056

15-18 months post

17

23518 ± 9840

TSP-1 [ng/ml]

before radioiodine

23

31246 ± 10680

0.72

7 days post

23

32761 ± 9046

3 months post

23

32507 ± 10892

6 - 8 months post

23

33751 ± 8830

 

15-18 months post

17

31758 ± 8319

 
Table 3

Descriptive statistics for MMP-2/TIMP-2 ratio and MMP-9/TIMP-1 ratio at five (5) consecutive visits – before and after radioiodine therapy, presented with probability values (p-values) of Kruskal-Wallis’ ANOVA for repeated measures design

 

VISIT:

n

Mean ± SD

p-value

MMP-2/TIMP-2

before radioiodine

23

2.96 ± 0.54

0.34

7 days post

21

2.65 ± 0.43

3 months post

23

2.68 ± 0.57

6 - 8 months post

23

3.00 ± 0.65

15-18 months post

17

2.86 ± 0.63

MMP-9/TIMP-1

before radioiodine

23

4.16 ± 3.19

0.042

7 days post

21

3.40 ± 2.06

3 months post

23

3.39 ± 1.47

6 - 8 months post

23

3.00 ± 1.95

 

15-18 months post

17

2.92 ± 1.68

 
https://static-content.springer.com/image/art%3A10.1186%2F1756-6614-6-9/MediaObjects/13044_2013_Article_172_Fig1_HTML.jpg
Figure 1

Concentrations of thrombospondin-1 (TSP-1) before and after radioiodine administration at consecutive time-points (visits 1–5), p=0.72 (Kruskal-Wallis’ ANOVA for repeated measures design).

https://static-content.springer.com/image/art%3A10.1186%2F1756-6614-6-9/MediaObjects/13044_2013_Article_172_Fig2_HTML.jpg
Figure 2

Concentrations of adiponectin before and after radioiodine administration at consecutive time-points (visits 1–5), p < 0.01 (Kruskal-Wallis’ ANOVA for repeated measures design).

https://static-content.springer.com/image/art%3A10.1186%2F1756-6614-6-9/MediaObjects/13044_2013_Article_172_Fig3_HTML.jpg
Figure 3

The ratio of concentrations of matrix metalloproteinases and their respective inhibitors at consecutive time-points (visits 1–5). Matrix metalloproteinase-2 (MMP-2) to tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) ratio, p = 0.34 (Kruskal-Wallis’ ANOVA for repeated measures design) before radioiodine administration and at all subsequent time-points.

https://static-content.springer.com/image/art%3A10.1186%2F1756-6614-6-9/MediaObjects/13044_2013_Article_172_Fig4_HTML.jpg
Figure 4

The ratio of concentrations of matrix metalloproteinases and their respective inhibitors at consecutive time-points (visits 1–5). Matrix metalloproteinase-9 (MMP-2) to tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) ratio, p < 0.05 (Kruskal-Wallis’ ANOVA for repeated measures design) before radioiodine administration and at all subsequent time-points.

Analysis of concentrations of MMPs and their inhibitors revealed no significant change in serum MMP-9 throughout the study, but an increase in MMP-2 (from 393±106 ng/ml, to 774±424 ng/ml) and TIMP-1 (from 177±76 ng/ml to 296±118 ng/ml), visit 1 to visit 5 respectively, p < 0.01. Further analysis, presented in Table 3, Figures 3 and 4, revealed, however, no significant change in MMP-2/TIMP-2 ratio. In contrast, there was a significant decrease in MMP-9/TIMP-1 ratio (p < 0.05), suggestive of possible decrease in concentrations of free MMP-9.

Discussion

To the best of our knowledge, this is the first study where concentrations of TSP-1 were assessed before and after treatment with radioiodine. Though this is a negative observation, the lack of any significant change of serum TSP-1 after treatment with radioiodine is indeed highly reassuring. TSP-1 which represents, besides thyroglobulin, the main protein secreted by thyroid cells has been found to play a role in the process of folliculogenesis [22], and inhibition of apoptosis of thyroid cells [23]. Furthermore, it has recently been found that TSP-1 directly promotes progression of papillary thyroid carcinoma, and namely BRAF(V600E), i.e. the most common somatic mutation in papillary thyroid carcinoma, requires activation of several other genes, including TSP-1, in order to facilitate tumor invasion and metastasis [24, 25]. Sid et al. [26] also demonstrated that the aggressive behavior of human thyroid malignant cells was closely correlated to the amount of TSP-1. They also demonstrated that exogenously added TSP-1 stimulated by two-fold the invasiveness of follicular thyroid carcinoma cells, while the use of specific anti-TSP-1 blocking antibodies led to a drastic inhibition of the basal follicular thyroid carcinoma cell invasion. In such context, the lack of any significant change in serum TSP-1 might signify that radioiodine treatment of thyrotoxicosis is unlikely to influence the development of subsequent thyroid cancer. It should be, however, strongly emphasized that that the observed lack of any significant changes in serum concentrations of TSP-1, must be also confirmed on a tissue levels, i.e. by studies of expression of TSP-1 following radioiodine treatment in thyroid cells.

Our study is also an extension of our previous report [27], where we demonstrated an unequivocal rise in serum adiponectin at three months after radioiodine administration. In this paper we have prospectively carried out our observations up to 15–18 months after radioiodine treatment, and so we have demonstrated that raised adiponectin concentrations persisted at all subsequent time-points. In our opinion, this implies that an increase in serum adiponectin is a sustained phenomenon, while longitudinal and prospective nature of our study diminishes the chance of possible type I (i.e., false positive) statistical error. The observed sustained increase in vasoprotective adiponectin is reassuring, given some recent controversies regarding cardiovascular safety of treatment with radioactive iodine. As mentioned above [6, 7], adiponectin improves insulin sensitivity and exerts anti-atherosclerotic effects in blood vessels. Indeed there are some studies [28] suggestive that the plasma leptin/adiponectin ratio predicts first cardiovas-cular event at least in men. Furthermore many cancer cell lines express adiponectin receptors, and adiponectin in vitro limits cell proliferation and induces apoptosis. Recent in vitro studies demonstrate the antiangiogenic and tumor growth-limiting properties of adiponectin [29]. It is to be recalled, however, that the significance of total adiponectin concentrations as a marker of a risk of cardiovascular disease has been recently questioned [30, 31].

Current study has also helped to clarify issues associated with changes of concentrations of MMPs and their inhibitors following radioiodine administration. In particular, we have demonstrated that though there was a significant increase in concentrations of MMP-2, that was no significant change in MMP-2/TIMP-2 ratio; the latter possibly being a result of a concomitant (though not significant) increase in TIMP-2 concentrations (from 136±44 ng/ml to 168±41 ng/ml). In contrast, there was no change in serum MMP-9 concentrations but there was a significant increase in TIMP-1 concentrations, with subsequent fall in MMP-9/TIMP-1 ratio. It should be mentioned that TIMP-2 is the principal inhibitor of MMP-2, while TIMP-1 is the principal inhibitor of MMP-9 [32], hence these results are suggestive of possible fall in free (i.e., biologically active) MMP-9 concentrations following radioiodine treatment. Interestingly, the observed increase of serum TIMP-1 concentrations seems to be independent of TSP-1, even though there is some evidence that TSP-1 induced expression of TIMP-1 in follicular thyroid carcinoma cells [33]. Therefore, our data support a notion - expressed previously - that treatment with radioactive iodine appears safe [34], as evidenced in children treated with radioactive iodine for Graves’ disease [35]. We have, already mentioned in our previous paper [27] that cardiovascular safety of radioactive iodine would also depend on meticulous follow-up of patients who undergo this treatment, as efforts must be made to detect and to treat radioiodine-induced hypothyroidism. If this is not done properly, then hypothyroidism per se might increase a risk of subsequent cardiovascular disease [3638]. It should also be mentioned that stable concentrations of MMPs, with possible fall of free MMP-9, do not support a notions of significant involvement of MMPs in the development of neoplasms following treatment with radioactive iodine. In this context, we note that large study of Ron et al. [39], based on a data from 35 593 subjects, failed to reveal an increase in cancer mortality in subjects treated with radioiodine.

Conclusions

In summary, results of our study are reassuring in terms cardiovascular and neoplastic safety of radioiodine treatment of thyrotoxicosis. In particular, administration of radioiodine does not alter serum concentrations of proinflammatory and procancerogenic TSP-1, and is associated with a sustained increase in serum adiponectin. Furthermore, there is no change in MMP-2/TIMP-2 ratio, with an increase in TIMP-1, and a fall of MMP-9/TIMP-1 ratio is recorded, the latter possibly indicative of a fall in free MMP-9 concentrations. However, it must be stressed that in our study we assessed concentrations of indirect markers associated with the risk of cardiovascular and neoplastic diseases, which cannot be regarded as surrogates of hard clinical end-points, such as morbidity and mortality.

Declarations

Acknowledgements

The study was supported by the grant of the Ministry of Science and Higher Education of Poland – No. NN402476637 (2009) (grant No. 507-11-384 of Medical University, Lodz) and by statutory funds from the Medical University of Lodz, Poland - No. 503/1-107-03/503-01.

Authors’ Affiliations

(1)
Department of Endocrinology & Metabolic Diseases, Medical University of Lodz, Polish Mother’s Memorial Hospital – Research Institute
(2)
Department of Endocrinology, Diabetes & Isotope Therapy, Medical University of Wroclaw
(3)
Department of Quality Control & Radiation Protection, Medical University of Lodz

References

  1. Raffetto JD, Khalil RA: Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008, 75: 346–359. 10.1016/j.bcp.2007.07.004PubMed CentralPubMedView ArticleGoogle Scholar
  2. Nichols L, Lagana S, Parwani A: Coronary artery aneurysm: a review and hypothesis regarding etiology. Arch Pathol Lab Med 2008, 132: 823–828.PubMedGoogle Scholar
  3. Newby AC: Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med 2007, 17: 283–253.View ArticleGoogle Scholar
  4. Phatharajaree W, Phrommintikul A, Chattiparon N: Matrix metalloproteinases and myocardial infarction. Can J Cardiol 2007, 23: 727–733. 10.1016/S0828-282X(07)70818-8PubMed CentralPubMedView ArticleGoogle Scholar
  5. Rosell A, Lo EH: Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol 2008, 8: 82–89. 10.1016/j.coph.2007.12.001PubMedView ArticleGoogle Scholar
  6. Siasos G, Tousoulis D, Kollia C, Oikonomou E, Siasou Z, Stefanadis C, Papavassiliou AG: Adiponectin and cardiovascular disease: mechanisms and new therapeutic approaches. Curr Med Chem 2012, 19: 1193–1209. 10.2174/092986712799320583PubMedView ArticleGoogle Scholar
  7. Harada S, Fujita-Hamabe W, Tokuyama S: Ischemic stroke and glucose intolerance: a review of the evidence and exploration of novel therapeutic targets. J Pharmacol Sci 2012, 118: 1–13. 10.1254/jphs.11R04CRPubMedView ArticleGoogle Scholar
  8. Tan BK, Syed F, Lewandowski KC, O'Hare JP, Randeva HS: Circadian oscillation of circulating prothrombotic thrombospondin-1: ex vivo and in vivo regulation by insulin. J Thromb Haemost 2008, 6: 1827–1830. 10.1111/j.1538-7836.2008.03123.xPubMedView ArticleGoogle Scholar
  9. Varma V, Yao-Borengasser A, Bodles AM, Rasouli N, Phanavanh B, Nolen GT, Kern EM, Nagarajan R, Spencer HJ 3rd, Lee MJ, Fried SK, McGehee RE Jr, Peterson CA, Kern PA: Thrombospondin-1 is an adipokine associated with obesity, adipose inflammation, and insulin resistance. Diabetes 2008, 57: 432–439.PubMed CentralPubMedView ArticleGoogle Scholar
  10. Xia Y, Dobaczewski M, Gonzalez-Quesada C, Chen W, Biernacka A, Li N, Lee DW, Frangogiannis NG: Endogenous thrombospondin 1 protects the pressure-overloaded myocardium by modulating fibroblast phenotype and matrix metabolism. Hypertension 2011, 58: 902–911. 10.1161/HYPERTENSIONAHA.111.175323PubMed CentralPubMedView ArticleGoogle Scholar
  11. Prabakaran D, Kim P, Kim KR, Arvan P: Polarized secretion of thrombospondin is opposite to thyroglobulin in thyroid epithelial cells. J Biol Chem 1993, 268: 9041–9048.PubMedGoogle Scholar
  12. Ghoneim C, Soula-Rothhut M, Rothhut B: Thrombospondin-1 in differentiated thyroid cancer: Dr. Jekyll and Mr. Hyde. Connect Tissue Res 2008, 49: 257–260. 10.1080/03008200802147795PubMedView ArticleGoogle Scholar
  13. Osman F, Gammage MD, Sheppard MC, Franklyn JA: Cardiac dysrhythmias and thyroid dysfunction: The hidden menace? J Clin Endocrinol Metab 2002, 87: 963–967. 10.1210/jc.87.3.963PubMedView ArticleGoogle Scholar
  14. Franklin JA, Sheppard MC, Maisonneuve P: Thyroid function and mortality in patients treated for hyperthyroidism. JAMA 2005, 294: 71–80. 10.1001/jama.294.1.71View ArticleGoogle Scholar
  15. Vőlzke H, Schwahn C, Wallaschofski H, Dőrr M: The association of thyroid dysfunction with all-cause and circulatory mortality: Is there a causal relationship? J Clin Endocrinol Metab 2007, 92: 2421–2429. 10.1210/jc.2007-0179PubMedView ArticleGoogle Scholar
  16. Belchetz P, Hammond P: Mosby’s Color Atlas and Text of Diabetes and Endocrinology. Elsevier Science Ltd; 2003:254–255. chapter 17Google Scholar
  17. Rivkees SA, Dinauer C: An optimal treatment for pediatric Graves’ disease is radioiodine. J Clin Endocrinol Metab 2007, 92: 797–800.PubMedView ArticleGoogle Scholar
  18. Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J: Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab 2007, 92: 2190–2196. 10.1210/jc.2006-2321PubMedView ArticleGoogle Scholar
  19. Vanderpump M: Cardiovascular and cancer mortality after radioiodine treatment of hyperthyroidism. J Clin Endocrinol Metab 2007, 92: 2033–2035. 10.1210/jc.2007-0837PubMedView ArticleGoogle Scholar
  20. Beierwaltes WH: The treatment of hyperthyroidism with iodine-131. Semin Nucl Med 1978, 8: 95–103. 10.1016/S0001-2998(78)80010-5PubMedView ArticleGoogle Scholar
  21. Jastrzębska H, Gietka-Czernel M, Zgliczyński S: Therapy of benign thyroid disease with iodide −131. Endokrynol Pol - Polish J Endocrinol 2003, 54: 187–194.Google Scholar
  22. Pellerin S, Croizet K, Rabilloud R, Feige JJ, Rousset B: Regulation of the three-dimensional organization of thyroid epithelial cells into follicle structures by the matricellular protein, thrombospondin-1. Endocrinology 1999, 140: 1094–1103. 10.1210/en.140.3.1094PubMedView ArticleGoogle Scholar
  23. Rath GM, Schneider C, Dedieu S, Sartelet H, Morjani H, Martiny L, El Btaouri H: Thrombospondin-1 C-terminal-derived peptide protects thyroid cells from ceramide-induced apoptosis through the adenylyl cyclase pathway. Int J Biochem Cell Biol 2006, 38: 2219–2228. 10.1016/j.biocel.2006.07.004PubMedView ArticleGoogle Scholar
  24. Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E, Finn S, Jarzab B, Hodin RA, Pontecorvi A, Nose V, Lawler J, Parangi S: BRaf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci USA 2010, 107: 10649–10654. 10.1073/pnas.1004934107PubMed CentralPubMedView ArticleGoogle Scholar
  25. Nucera C, Lawler J, Parangi S: BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res 2011, 71: 2417–2422. 10.1158/0008-5472.CAN-10-3844PubMed CentralPubMedView ArticleGoogle Scholar
  26. Sid B, Langlois B, Sartelet H, Bellon G, Dedieu S, Martiny L: Thrombospondin-1 enhances human thyroid carcinoma cell invasion through urokinase activity. Int J Biochem Cell Biol 2008, 40: 1890–1900. 10.1016/j.biocel.2008.01.023PubMedView ArticleGoogle Scholar
  27. Lewiński A, Brona A, Lewandowski K, Skowrońska-Jóźwiak E, Milewicz A: In contrast to matrix metalloproteinases, serum adiponectin concentrations increase after radioiodine treatment of thyrotoxicosis. Thyroid Res 2012, 5: 12. 10.1186/1756-6614-5-12PubMed CentralPubMedView ArticleGoogle Scholar
  28. Kappelle PJ, Dullaart RP, van Beek AP, Hillege HL, Wolffenbuttel BH: The plasma leptin/adiponectin ratio predicts first cardiovascular event in men: A prospective nested case–control study. Eur J Intern Med 2012, 23: 755–759. 10.1016/j.ejim.2012.06.013PubMedView ArticleGoogle Scholar
  29. Dalamaga M, Diakopoulos KN, Mantzoros CS: The role of adiponectin in cancer: A review of current evidence. Endocr Rev 2012, 33: 547–594. 10.1210/er.2011-1015PubMed CentralPubMedView ArticleGoogle Scholar
  30. Kanhai DA, Kranendonk ME, Uiterwaal CS, van der Graaf Y, Kappelle LJ, Visseren FL: Adiponectin and incident coronary heart disease and stroke. A systematic review and meta-analysis of prospective studies. Obesity Rev 2013, 14: 555–567. 10.1111/obr.12027View ArticleGoogle Scholar
  31. Hao G, Li W, Guo R, Yang JG, Wang Y, Tian Y, Liu MY, Peng YG, Wang ZW: Serum total adiponectin level and the risk of cardiovascular disease in general population: A meta-analysis of 17 prospective studies. Atherosclerosis 2013, 228: 29–35. 10.1016/j.atherosclerosis.2013.02.018PubMedView ArticleGoogle Scholar
  32. Brew K, Dinakarpandian D, Nagase H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000, 1477: 267–283. 10.1016/S0167-4838(99)00279-4PubMedView ArticleGoogle Scholar
  33. Soula-Rothhut M, Coissard C, Sartelet H, Boudot C, Bellon G, Martiny L, Rothhut B: The tumor suppressor PTEN inhibits EGF-induced TSP-1 and TIMP-1 expression in FTC-133 thyroid carcinoma cells. Exp Cell Res 2005, 304: 187–201. 10.1016/j.yexcr.2004.10.026PubMedView ArticleGoogle Scholar
  34. Franklyn JA: Thyroid disease and its treatment: short- and long-term consequences. J R Coll Physicians Lond 1999, 33: 564–567.PubMedGoogle Scholar
  35. Foley TP Jr, Charron M: Radioiodine treatment of juvenile Graves’ disease. Exp Clin Endocrinol Diabet 1997,105(Suppl 4):61–65.View ArticleGoogle Scholar
  36. Mansourian AR: A review on cardiovascular diseases originated from subclinical hypothyroidism. Pak J Biol Sci 2012, 15: 58–67. 10.3923/pjbs.2012.58.67PubMedView ArticleGoogle Scholar
  37. Danzi S, Klein I: Thyroid hormone and the cardiovascular system. Med Clin North Am 2012, 96: 257–268. 10.1016/j.mcna.2012.01.006PubMedView ArticleGoogle Scholar
  38. Duntas LH, Brenta G: The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am 2012, 96: 269–281. 10.1016/j.mcna.2012.01.012PubMedView ArticleGoogle Scholar
  39. Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, Harris BS 3rd, Hoffman DA, McConahey WM, Maxon HR, Preston-Martin S, Warshauer ME, Wong FL, Boice JD Jr: Cancer mortality following treatment for adult hyperthyroidism. cooperative thyrotoxicosis therapy follow-up study group. JAMA 1998, 280: 347–355. 10.1001/jama.280.4.347PubMedView ArticleGoogle Scholar

Copyright

© Lewinski et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement